Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mhspc) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (adt) with or without docetaxel (doc): long-term results from 2 phase 3 trials from the stampede platform protocol

JOURNAL OF UROLOGY(2023)

引用 0|浏览9
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要